An Insight Into Risk Assessment and Reformulation of Drug Products Manufactured Using Benzene Grade Carbomer: A...

Area of Science:

• Pharmaceutical Sciences
• Drug Formulation
• Regulatory Affairs

Background:

• The US FDA issued new guidance in December 2023 concerning benzene-grade carbomer formulations.
• This guidance necessitates risk assessment, product testing, and reformulation for pharmaceutical manufacturers.
• The deadline for discontinuing products with benzene-grade carbomers was extended by the US Pharmacopeia to August 1, 2026.

Purpose of the Study:

• To provide an in-depth analysis of risk assessment and reformulation strategies for benzene-grade carbomers.
• To guide pharmaceutical manufacturers in navigating US FDA guidelines for formulation safety and compliance.
• To explore opportunities for developing improved drug formulations with enhanced safety profiles.

Main Methods:

• Review of US FDA guidance on benzene-grade carbomers.
• Analysis of risk assessment methodologies for pharmaceutical formulations.
• Examination of reformulation processes across various dosage forms.
• Inclusion of specific case studies to illustrate practical application.

Main Results:

• Identification of critical steps in risk assessment and reformulation processes.
• Demonstration of strategies for ensuring compliance with regulatory standards.
• Highlighting the importance of adapting to new regulatory landscapes.
• Showcasing the potential for innovation in drug excipient selection.

Conclusions:

• The US FDA's restriction on high-benzene carbomers is a positive step towards patient safety.
• Manufacturers can leverage this review to effectively manage reformulation challenges.
• This work facilitates the development of safer and compliant pharmaceutical products.
• Opportunities exist for creating next-generation medicines with superior safety profiles.